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Chronic hepatitis B infection progresses from an asymptomatic persistently infected state to chronic hepatitis, cirrhosis,
decompensated liver disease, and/or hepatocellular carcinoma. About 3% of patients with chronic hepatitis develop cirrhosis
yearly, and about 5% of individuals with hepatitis B cirrhosis become decompensated annually. The outcome for patients with
decompensated cirrhosis is bleak. Lamivudine, the ﬁrst oral antiviral agent available for hepatitis B treatment is safe and eﬀective
and can improve or stabilize liver disease in patients with advanced cirrhosis and viraemia. Viral resistance restricts its prolonged
use. Entecavir and tenofovir are newer agents with excellent resistance proﬁle to date. These and some other antiviral agents are
being investigated for optimal use in this rather challenging patient group.
1.Introduction
Chronic hepatitis B virus (HBV) infection is a major global
public health problem with an estimated 1million deaths
yearly worldwide from complications of liver cirrhosis
namely, liver failure and hepatocellular cancer (HCC) [1, 2].
Up to 40% patients with chronic hepatitis B virus infection
develop serious complications during their lifetime. Up to
12% of patients with HBV cirrhosis die of liver failure, and
up to 10% perish from liver cancer [3, 4]. The prognosis for
patients with decompensated HBV cirrhosis is poor, with a
5-year survival of only 14% compared with 84% in patients
with compensated HBV cirrhosis [3]. The ultimate cure for
end stage liver disease is liver transplantation. Many patients
with advanced hepatitis B worldwide do not have accessto or
are not eligible for this treatment modality [1, 5]. This article
brieﬂy review the epidemiology and natural progression of
chronic hepatitis B infection and provides an update on the
medical management of patients with decompensated HBV
cirrhosis with particular emphasis on the use of available
antiviral agents.
2.PrevalenceofHepatitisBInfection
Hepatitis B virus (HBV) infection is endemic in the Asia
Paciﬁc region and in Africa. Up to 62% of the population
in China, up to 98% of the people in sub-Saharan Africa and
up to 80% of the populations in some Paciﬁc islands have
markers of HBV infection [6]. Chronic or persistent HBV
infection is deﬁned as the presence of hepatitis B surface
antigen (HBsAg) in the serum for longer than 6 months. It
is estimated that there are 350 million people with chronic
HBV infection worldwide (more than 5% of the world
population). More than 75% of these chronically infected
people live in Asia and a further 12%, (approximately
50 million) live in Africa. In many countries in the Asia
Paciﬁc region, 8–20% of the populations have chronic HBV
infection [7].
3. DiseaseProgressioninChronic
HepatitisBInfection
Chronic HBV infection can lead to chronic liver disease,
with a broad range of symptoms [8, 9]. The early phase
of the infection is typically asymptomatic with active virus
replication (HBVDNA > 20,000IU/mL) and very little liver
necroinﬂammation. Hepatitis B antigen (HBeAg) is present.
This phase, also called the immune-tolerant phase, can
last for several decades before the appearance of hepati-
tis symptoms. Persistent or episodic hepatic necroinﬂam-
mation (chronic hepatitis), with elevated serum alanine2 International Journal of Hepatology
aminotransferase (ALT) levels, characterizes this phase of
immune elimination of HBV. During this stage, HBeAg
and HBV DNA levels may progressively decrease and
seroconversion from HBeAg to HBe antibody (anti-HBe)
may occur [10, 11] .T h el o n g e rt h i sp e r i o do fa c t i v el i v e r
disease lasts, the higher the risk of irreversible liver damage.
Patients enter the third (inactive carrier) phase when HBV
replication is no longer detected and liver histology usually
stabilizes [10]. However low levels of the virus (HBVDNA <
2000IU/mL) can stillbe detected in the majority of patients,
and reactivation of HBV replication with exacerbation of
disease can occur [12–14]. Some patients may progress to
cirrhosis and HCC during this phase of apparent inactivity.
In the Asia-Paciﬁc region, the annual incidence of
chronic hepatitis in asymptomatic, persistently infected
individuals ranged from 0.84 to 2.7%. The annual incidence
of cirrhosis among patients with chronic hepatitis B was
reported to be approximately 1.0–2.4%. The annual rates of
progression from compensated cirrhosis to decompensated
cirrhosiswerearound4.6%[15,16].Theannualincidenceof
HCC ranged from 0.02–0.65% in asymptomatic persistently
infected individuals, 0.27–1.0% in patients with chronic
hepatitis B and 3.0–6.6% in compensated HBV cirrhosis
[6]. The annual progression rate from decompensated HBV
cirrhosis to HCC was around 7.1%. The 5-year mortality
rate from decompensated cirrhosis was from 41% to 67%
[17, 18].
Factors associated with rapid disease progression in HBV
infected patients include the male gender, increasing age,
viraemia with repeated hepatic ﬂares or prolonged periods
of liver necroinﬂammation, and alcohol use; confection with
other viruses such as hepatitis C, hepatitis D, and human
immunodeﬁciency virus (HIV); use of immunosuppressive
agents, platelets less than 150,000/mL and serum bilirubin
more than 1.1mg/dL (18.8umol/L) [19–26]. Patients with
HBV cirrhosis and active viral replication are at increased
risk of developing progressive liver disease and death [4, 27].
Loss of HBeAg and seroconversion to HBe antibody (anti-
HBe)withreductioninHBVDNAlevelshavebeenassociated
with a 55% reduction in the risk of death [3]. Suppression
of HBV replication with loss of HBeAg and or HBsAg is
therefore an important event in the natural history and
treatment of chronic HBV infection.
4.LiverCirrhosisandDecompensation
The mean age of onset of cirrhosis in chronic HBV infection
acquired during childhood, is about 40 years and complica-
tions become clinically evident 3 to 5 years later. It is esti-
mated that the annual rate of hepatic decompensation is 4%
in cirrhotic patients with viraemia and 1% in those without
viraemia [14]. The development of jaundice, ascites, hepatic
encephalopathy (HE) or bleeding oesophageal varices sig-
nals decompensation. Acute decompensation is usually sec-
ondary to a hepatitis ﬂare or spontaneous bacterial infection
which further impairs the already decreased hepatic reserve.
The other form is a gradually developing end-stage event.
As mentioned previously, the outlook for decompensated
cirrhosis is rather bleak with a 5-year survival of 14%
compared with 84% in patients with compensated cirrhosis
[3].
5. GeneralManagement of Patients with
Decompensated LiverCirrhosis
5.1. Assessment of Disease Severity. Clinical examination
and measurement of blood parameters like serum albumin,
bilirubin, creatinine and prothrombin time can help deter-
mine the severity and progression of liver disease.The Child-
Turcotte-Pugh (CTP) score and Model for End Stage Liver
Disease (MELD) score are two indices that are usually used
to determine the severity of liver disease in patients with
cirrhosis [28]( Table 1). The CTP score was developed to
determine preoperative risk of patients with cirrhosis for
portal-systemic shunt surgery. It is calculated by adding
the individual scores assigned to ranges of serum albumin
level, serumbilirubin level, prothrombin time, the presence
and degree of ascites and hepatic encephalopathy. The
CTP score is easily calculated at the patient’s bedside. The
MELD score was initially developed to predict short-term
mortality following transjugular intrahepatic portosystemic
shunt (TIPS) placement. It was later modiﬁed to predict
short-term mortality in patients with diﬀerent causes of
cirrhosis [28] and is now being used to predict waiting
list mortality of patients listed for liver transplantation.
The MELD score uses objective and standardized labora-
tory parameters (i.e., serum bilirubin, prothrombin time
(international normalized ratio, INR), and creatinine) over a
broader range of possible values to provide a more dynamic
assessment of liver disease severity. Calculating the MELD
score needs a calculator and cannot be easily done at the
patient’s bedside.
5.2. Prevent Further Liver Damage. Alcohol, potentially
hepatotoxic drugs including medications that may increase
the risk of gastrointestinal bleeding (nonsteroidal anti-
inﬂammatory agents), or renal insuﬃciency should be
avoided. Patients with decompensated HBV cirrhosis should
be vaccinated against hepatitis A if not already immune as
superimposed hepatitis A infection could be fatal [29, 30].
Asmentioned,thepresenceofHBeAgorHBVDNAindicates
continuing viral replication. International guidelines suggest
treating patients with chronic hepatitis B cirrhosis if serum
HBV DNA present (EASL) or more than 2,000IU/mL
(AASLD/APASL). The threshold for antiviral therapy is
usually lower for decompensated liver disease [31–33].
5.3. Prevent and Treat Complications of Cirrhosis. Gas-
troscopy should be performed on initial presentation and
every two years afterwards in patients with liver cirrhosis to
look for oesophageal and gastric varices [34]. If these are
found, appropriate treatment should be instituted. Variceal
bleeding can be prevented in grade 3 and 4 varices by
oral beta blockers and endoscopicvariceal ligation [35].
Treatment of variceal bleeding should include antibiotics to
prevent spontaneous septicaemia. Transjugular intrahepatic
portosystemic stent (TIPS) placement may be required in
patients with uncontrolled or recurrent variceal bleedingInternational Journal of Hepatology 3
Table 1: Assessing liver disease severity in decompensated HBV
cirrhosis.
Scale (range) Mild Moderate Severe Ref.
CTP (5 to 15) 5-6 (A) 7–9 (B) 10–15 (C) Keeﬀe, 2001
[43]
MELD (6–40 ) 6–10 11–24 25–40 Kamath et al.,
2001 [28]
[36]. TIPS may also be considered in patients with refractory
ascites if their liver function is not severely impaired, if they
are less than 70 years old, and if hepatic encephalopathy
is absent [37]. Spontaneous bacterial peritonitis (SBP) and
other spontaneous infections should be treated straight
away with broad spectrum antibiotics, (e.g., cephalosporins
or amoxicillin/clavulanate) and albumin to prevent the
hepatorenal syndrome [38]. Prophylactic antibiotics should
be given to patients with a history of SBP [39].
Hepatic encephalopathy is a severe complication of
cirrhosis and is related to the eﬀect of ammonia. Recent
evidence suggests that the eﬀect of ammonia on the brain
is triggered by inﬂammation caused by spontaneous infec-
tions. The mainstay of therapy is antibiotics (neomycin,
rifaximin, vancomycin) and nonabsorbable disaccharides.
Protein restriction is no longer recommended and can
worsen the nutritional status if maintained [40]. The
development of HE in patients with cirrhosis is associated
with a less than 50% survival at 1 year. Liver transplant
should be considered. Hepatorenal syndrome (HRS) is a
potentially lethal complication and is usually triggered by
infections. Besides antibiotics, it can be eﬀectively treated
with vasoconstrictors associated with intravenous albumin,
TIPS, and albumin dialysis [41].
5.4. HCC Surveillance. Patients should undergo HCC
surveillance by determining serum alpha-fetoprotein (AFP)
levels and liver ultrasound every 6 months [32]( Table 2).
Early stage HCC can be successfully managed by loco-
regional ablative therapy [42] and may change the priority
for transplantation [43].
6. LiverTransplantation
Liver transplantation is a well-established modality for treat-
ing patients with advanced irreversible liver failure for which
there are no alternative treatments [43]. Approximately 5%
of liver transplants performed in the United States annually
are for hepatitis B [44], and the proportion is higher in
the Asia Paciﬁc region [33]. All cirrhotic patients with a
CTP score of more than 7 and a complication of portal
hypertension such as ascites, encephalopathy, or variceal
bleeding should be referred for liver transplant evaluation
[43]. Selected patients with unresectable HCC that is less
than 5cm in maximal diameter should also be referred for
liver transplant evaluation.
Immunoprophylaxisusingprolongedhigh-dosehepatitis
B immunoglobulin (HBIG) has resulted in excellent patient
and graft survival rates for patients with decompensated
HBV cirrhosis who were viraemic pretransplant [5, 45].
Up to 40% of patients with pretransplant viraemia who
received HBIG alone developed recurrent HBV infection
[5]. This risk of posttransplant HBV recurrence can be
reduced by antiviral suppression of HBV replication prior to
transplantation and maintenance of antiviral therapy after
transplantation [33]. Liver transplantation is not available
to many patients with decompensated HBV infection in the
Asia Paciﬁc region, and the only recourse for these patients is
antiviral therapy.
7. AntiviralTreatment
Suppression of HBV replication has resulted in reduction
of hepatic necroinﬂammation and improvement of liver
function in patients with CHB cirrhosis and liver decompen-
sation. Patients with decompensated HBV-cirrhosis should
be considered for antiviral therapy irrespective of HBVDNA
levels.
7.1. Interferon-Alpha. Interferon-alpha or its pegylated ver-
sion is safe and eﬀective in patients with chronic hepatitis
B and in selected patients with compensated HBV cirrhosis
[46, 47]. It has been associated with life-threatening hepatitis
ﬂares (up to 50%) and infectious complications (28%)
in prospective trials of patients with decompensated HBV
cirrhosis even when used in very low doses [48, 49]. It is
generally discouraged in patients with decompensated HBV
cirrhosis.
7.2. Oral Antiviral Agents. Most practice guidelines recom-
mend prescribing an oral nucleos(t)ide analogue (and not
interferon) for patients with decompensated HBV cirrhosis
independent of the patients serum ALT, HBV DNA level, and
HBeAg status [31–33]. These recommendations are largely
based upon open-label studies of lamivudine and adefovir in
this group of patients. These studies reported that antiviral
therapy was associated with improved outcomes including
a delay or prevention in the need for liver transplantation
(Table 1)[50–53].Abiphasicsurvivalpatternwasnotedwith
mostdeathsoccurringwithintheﬁrst6monthsoftreatment;
patients with higher pretreatment bilirubin, creatinine, and
HBV DNA levels were at greatest risk for early death while
early suppression of HBV replication was not associated with
more favorable outcomes [51].
8. Lamivudine
Lamivudine is an orally administered nucleoside analogue
that inhibits HBVDNA synthesis by incorporating active
triphosphate (3TC-TP) into growing DNA chains. It sup-
pressed serum HBV DNA to undetectable levels (using
hybridization assays) in more than 90% of patients with
compensated chronic hepatitis B. This was associated with
improved serum ALT levels as well as liver histology at 12
months [54, 55]. It is generally safe and well tolerated with
as i d ee ﬀect proﬁle similar to that of placebo [54], making it
the preferred treatment compared to IFN for patients with4 International Journal of Hepatology
Table 2: General Recommendations in Decompensated HBV Cirrhosis.
Assess disease severity Clinical, liver biochemistry, creatinine, INR CTP score, MELD score
Prevent further liver damage
Avoid alcohol
Avoid hepatotoxic drugs
Avoid Immunosuppression. Antiviral prophylaxis if necessary
Avoid Aspirin/NSAIDS
Hepatitis A vaccination in nonimmune
Prevent and treat Laboratory and clinical assessment 3 to 6 monthly
Complications
Endoscopy at presentation and treat varices accordingly
Be aware of spontaneous infections and treat appropriately
Salt and ﬂuid restriction in ascites control, TIPS
Albumin and terlipressin in hepatorenal syndrome
Antibiotics and nonabsorbable disaccharides in hepatic encephalopathy
Low-protein diet not essential
Regular AFP measurement and ultrasound examination
Antiviral therapy
Entecavir
Lamivudine. Replace with entecavir monotherapy, Tenofovir monotherapy, or add on adefovir in
cases of lamivudine resistance
Tenofovir
Telbivudine
Adefovir
Liver transplantation Pretransplant antiviral therapy in viraemic subjects and immunoprophylaxis using HBIG after
transplant
decompensated HBV cirrhosis. Hepatitis ﬂares during treat-
ment usually indicate the occurrence of resistant mutations.
The recommended dose of lamivudine is 100mg daily. Dose
modiﬁcation is necessary in renal impairment (reduction)
and in patients with HIV coinfection (increment). Once
treatment is initiated, it should be maintained indeﬁnitely
even in patients who appear to have dramatic clinical
improvement and in those undergoing liver transplantation.
Development of lamivudine resistance begins after 6
months of treatment, and up to 70% of patients become
lamivudine resistant after5 yearsof continuous therapy [32].
Resistance to lamivudine is manifested by the reappearance
of HBV DNA after its initial suppression with a variable
increase in serum ALT levels [55, 56]. The most common
mutation involves the YMDD motif of the HBV polymerase
gene (M204V/I) and is frequently accompanied by another
mutation in an upstream region (L180M) [57]. Diagnostic
assays for lamivudine-resistant mutants are commercially
available. Hepatitis ﬂares are not uncommon with the emer-
gence of YMDD mutants resulting in progressive worsening
of liver disease [58, 59] and can be fatal in patients with
decompensated disease.
Lamivudine resulted in a rapid suppression of HBV
DNA to undetectable levels (non-PCR-based assays) and
improvement in biochemical and clinical parameters in
both controlled and uncontrolled studies of patients with
decompensatedHBVcirrhosis[51,60–65].Twenty-threeout
of 35 decompensated HBV patients treated by Villeneuve
and colleagues showed a slow but marked improvement in
biochemical parameters and CTP scores [60]. Seven patients
underwent liver transplantation, and 5 patients died within
the ﬁrst 6 months of lamivudine treatment. Two of these
23 patients later perished (from SBP and HCC, resp.) and
3 developed lamivudine resistance.
Signiﬁcant improvement in CTP scores (8.3 versus 6.7)
and ALT levels (111 versus 58IU/L) were also noted in 18
Indians with decompensated HBV cirrhosis after a mean
treatment duration of 18 months using lamivudine [61].
Yao and Bass reported similar CTP score improvement in
13 patients with Child’s C cirrhosis given lamivudine and 5
of the patients were eventually taken oﬀ the liver transplant
waiting list [62]. Similar ﬁndings were also noted in 30
Greek patients with decompensated HBV cirrhosis given
lamivudine [63].
More than 80% of 154 patients with decompensated
HBVcirrhosishadsuppressionofHBVDNAtoundetectable
levels by the branched-chain DNA (bDNA) assay within
8 weeks of initiating lamivudine treatment by Fontana
and coworkers [51]. HBeAg loss was seen in 35% patients
and HBeAg seroconversion to anti-HBe occurred in 20%
of patients. The actuarial 3-year survival was 72% for all
patients and 88% for patients who survived beyond the ﬁrst
6 months of treatment.
In a study involving 77 HBsAg-positive liver transplant
candidates, Perrillo et al. reported stabilization or improve-
ment in liver disease severity with lamivudine in 27 patients
without transplants who were treated with lamivudine for a
median of 28 months [64]. The actuarial survival in these
patients appeared to be better than the survival in untreated
historical controls with decompensated HBV cirrhosis andInternational Journal of Hepatology 5
similar to that of patients with untreated compensated HBV
cirrhosis from an earlier observation [3].
Yao et al. noted that transplant candidates receiving
lamivudine were less likely to undergo transplantation than
untreated historical controls who were matched for age,
gender, and illness severity at the time of listing (35% versus
74%, P = .04) [65]. A signiﬁcantly greater proportion of the
lamivudine-treated patients experienced an improvement
≥3 points in their CTP scores compared with the untreated
historical controls (61% versus 0%, P = .0001). In a retro-
spective analysis of 309 North American HBsAg positive liver
transplant candidates, Fontana and his colleagues compared
the outcomes of 162 lamivudine-treated patients and 147
untreated patients [66]. The two groups were comparable in
liver disease severity before treatment. Treated patientswere
more likely to have evidence of active HBV replication.
Overall, the actuarial pretransplant and transplant-free sur-
vival was similar in the two groups and lamivudine had
no apparent eﬀect on liver disease severity in patients who
underwent transplantation. However, among the patients
whowerestillawaitingtransplantation,lamivudineappeared
to stabilize or improve liver disease severity.
Earlier studies using lamivudine in decompensated HBV
cirrhosis were not controlled, and control cohorts used
in later studies were either historical or non-randomised.
Inclusion criteria and therapeutic endpoints were also inho-
mogeneous. It was unclear whether patients in some of the
studies had acute hepatic decompensation secondary to a
recent hepatitis ﬂare as improvement upon viral suppression
is more likely in group than in patients with hepatic decom-
pensation secondary to end-stage liver disease [60, 61].
Other interventions that may have prolonged transplant-
free survival (e.g., TIPS, use of prophylactic antibiotics) may
have contributed to the observed improvements in clinical
outcomes. In spite of all these inadequacies, lamivudine
was found to be safe in patients with decompensated HBV
cirrhosis although not all patients beneﬁted from it [67].
Clinical improvement usually occurs between 3 to 6 months
of therapy and improvement might not occur if treatment is
started late. Pretreatment severity of liver disease (increased
bilirubin, low albumin, prolonged PT and raised creatinine)
is a more important predictor of early mortality than
antiviral response in this group of patients [51, 66]. Careful
monitoring is mandatory in patients with decompensated
liver disease treated with lamivudine as a hepatitis ﬂare from
resistant mutants can be fatal. Should molecular resistance
be detected add on therapy with adefovir dipivoxil or substi-
tutiontherapywithtenofovirorentecavirisadvised.Patients
with initial clinical improvement can develop complications
of cirrhosis and HCC even in the absence of lamivudine-
resistance.
9. Adefovir Dipivoxil
Adefovir dipivoxil is a prodrug of adefovir, an acyclic
nucleotide analog of adenosine monophosphate. Adefovir is
phosphorylated to the active metabolite, adefovir diphos-
phate, by cellular kinases. Adefovir diphosphate inhibits
HBV DNA polymerase (reverse transcriptase) by competing
with the natural substrate deoxyadenosine triphosphate and
by causing DNA chain termination after its incorporation
intoviralDNA[33].Ithasahighgeneticbarriertoresistance
and has the ability to suppress most lamivudine-resistant
mutants. Renal toxicity is rare with the dose of 10mg
daily (Table 3). Adefovir dipivoxil has been available for the
treatment of chronic hepatitis B since 2003 but has not
been evaluated as a primary treatment for patients with
decompensated cirrhosis.
In a compassionate use study involving 128 patients with
decompensated cirrhosis and 196 patients with recurrent
hepatitisBafterlivertransplant,additionofadefovirresulted
in a 3-4 log10 reduction in serum HBVDNA levels, which
was sustained throughout the course of treatment [52]. After
48 weeks of treatment, undetectable HBV DNA by PCR and
normal ALT was noted in 81% and 76% of the pretransplant
and 34% and 49% of the posttransplant patients, respec-
tively. More than 90% of the pretransplant patients had
improvement in their CTP scores, and 1-year survival was
84% for the pre- and 93% for the posttransplant patients.
Follow-up data on 226 pretransplant patients showed that
viral suppression was maintained in 65% of patients after 96
weeksoftreatmentwithaccompanyingimprovementinCTP
and MELD scores. Fourteen percent of patients died within
the ﬁrst year and at least 33% required liver transplantation
for long-term survival [53].
Arecentinterimreportshowednodiﬀerenceinmortality
rates after 24 weeks of treatment in 195 patients with
decompensated HBV cirrhosis randomized to adefovir or
e n t e c a v i r .T h i ss t u d yi si np r o g r e s s[ 68].
Although antiviral drug resistance is substantially less
common with adefovir monotherapy compared to lamivu-
dine, concerns remain regarding the slow rate of suppressing
HBV replication with adefovir as well as the potential
for dose-dependent nephrotoxicity in decompensated HBV
patients (up to 28% of patients had an increase in serum
creatinine ≥0.5mg/dL after 48 weeks of treatment [69, 70].
Until more data becomes available, adefovir should not
be recommended as ﬁrst-line treatment in patients with
decompensated HBV-cirrhosis. However, for patients with
worsening liver disease secondary to lamivudine resistance,
use of adefovir as a salvage therapy is an option.
10. Telbivudine
Telbivudine, a synthetic thymidine nucleoside analogue,
is active against HBV. It undergoes phosphorylation by
cellular enzymes to form the active metabolite, telbivudine
triphosphate which incorporates into viral DNA competing
with the natural substrate, thymidine triphosphate, and
causing DNA chain termination, resulting in inhibition of
HBV replication. It has demonstrated potent activity against
hepatitis B with a signiﬁcantly higher rate of response
and superior viral suppression compared with lamivudine
and adefovir [71]. It is generally well tolerated with a low
adverse eﬀect. It was approved by the FDA in late 2006.
HBV strains with reduced susceptibility to telbivudine have
emerged during therapy with the drug. Cross-resistance may6 International Journal of Hepatology
Table 3: Antiviral Agents with Activity against Wild Type and Lamivudine resistant HBV.
Agent Daily dose Side eﬀects Comments
Adefovir 10mg Dose-dependant nephrotoxicity Drug resistance after 12 months
Entecavir 1mg No major side eﬀects to date Drug resistance eventually in lamivudine-resistant mutants
Tenofovir 300mg Neuropathy, nausea, CPK elevations, Fanconi syndrome No drug resistance up to 4 years
occur among some nucleoside analogues active against HBV.
Lamivudine-resistant HBV with reduced susceptibility to
telbivudine has been observed. Some adefovir-resistant HBV
are also resistant to telbivudine.
Gane and colleagues conducted a double blind trial on
195 patients (70% Asians) with decompensated HBV liver
disease [72]. Patients were randomly assigned to receive
600mg telbivudine or 100mg lamivudine for 104 weeks.
About three-quarters were men, with a mean age of 52
years and 57% were HBeAg negative. In a 2-year intent-to-
treat analysis, more patients appeared to have undetectable
HBV DNA (<300copies/mL; 47% versus 36%, P = .15)
and ALT normalization (58% versus 50%, P = .25) in the
telbivudinetreatmentarmthaninthelamivudinearm.Using
a composite endpoint of undetectable HBV DNA and ALT
normalization, however, telbivudine performed signiﬁcantly
better than lamivudine (34% versus 24%, resp.; P = .004).
29%oftelbivudinerecipientsexperiencedviralbreakthrough
while on therapy, compared with 39% of lamivudine recip-
ients (P = .16). At the end of treatment, about 75%
of patients in both arms had stabilized or improved liver
disease, as indicated by changes from baseline in CTP scores.
Kidney function (indicated by glomerular ﬁltration rate)
modestly improved in the telbivudine arm, while worsening
in the lamivudine arm. Early (week 24) survival rates were
similar in the 2 study arms, 96% with telbivudine and 92%
with lamivudine. Long-term (week 104) survival rates were
96% and 83%, respectively, with a trend toward statistical
signiﬁcance.Seriousadverseeventswerecommon,consistent
with advanced liver disease, and they occurred with similar
frequency in both arms (55% of telbivudine recipients versus
61% of lamivudine recipients). No cases of rhabdomyolysis
or lactic acidosis were reported. The investigators con-
cluded that telbivudine was well tolerated with stabiliza-
tion of liver function and had comparable tolerability to
lamivudine.
11.Entecavir
Entecavir is a cyclopentyl guanosine analogue with potent
selective inhibition of the priming, DNA-dependent synthe-
sis, and reverse transcription functions of HBV polymerase.
It has demonstrated activity against both wildtype HBV and,
to a lesser extent, lamivudine-resistant HBV [73, 74]. It
suppressesHBVreplicationmorerapidlyandeﬀectivelythan
lamivudineoradefovirinpatientswithcompensatedchronic
HBV [75, 76]. It has an excellent resistance proﬁle after 5
years in nuycleosid(t)e na¨ ıve patients and does not have any
reported nephrotoxicity [77], It has been used to rescue a
small number of liver transplant recipients with lamivudine-
resistant HBV successfully [78].
Shim et al. demonstrated that 0.5mg entecavir daily
was eﬀective in treating 70 nucleoside na¨ ıve decompensated
HBV patients with nearly 90% achieving undetectable HBV
DNA (PCR) at 1 year [79]. The virological responses in
55 decompensated HBV patients treated for at least 1 year
were compared to 144 compensated patients treated with
entecavir from the same center. The mean MELD (11.5
versus 7) and CTP scores (8.1 versus 5.3) were signiﬁcantly
higher in the decompensated patients. The proportion of
HBeAg positive patients and mean HBV DNA levels were
similar in the two groups. Overall, the 1-year transplant-
free survival rate was 87% in the decompensated patients.
As seen previously with lamivudine, the majority of adverse
outcomes occurred during the ﬁrst 6 months of therapy
with the nine patients having more severe liver failure at
entry. Baseline HBV DNA levels, HBe antigenaemia and
response to therapy were similar in both survivors and
non-survivors or those who underwent transplant. Nearly
50% of the entecavir treated patients had a clinically
signiﬁcant decrease in their CTP score of >2 points at 1-year.
HBeAg loss in both the decompensated and compensated
patients was remarkably high at 1 year (48% vs 41%). HBV
DNA suppression was maintained during followup with no
instances of viral rebound or entecavir-resistant HBV. Not
all decompensated patients improved with entecavir therapy.
Twelve patients (22%) showed no change in their CTP score
at 1-year (4 patients had aggravation or their liver disease
with worsening CTP scores). Five patients developed HCC
during followup.
A retrospective analysis of 107 decompensated patients
(mean age 53 years; 70.1% men; 42% HBeAg positive)
treated with lamivudine or entecavir showed signiﬁcantly
lower serum HBV DNA levels and prevalence of patients
with undetectable HBV DNA (PCR) at 3, 6, 9, and 12
months after treatment in entecavir-treated patients than in
the lamivudine group. Serum ALT levels, CTP and MELD
score, and the prevalence of patients with improved CTP
scores at 3, 6, 9, and 12 months did not diﬀer between two
groups. The prevalence of HBeAg seroconversion and HCC
and mortality also did not diﬀer between two groups while
that of viral breakthrough was signiﬁcantly more frequent in
the lamivudine-treated patients [80].
Liaw et al. randomized 195 patients with decompensated
HBV to entecavir (1.0mg per day) or aderovir (10mg per
day) [68], One-third (34%) of patients had lamivudine-
resistant HBV. Interim results at week 24 demonstrated a
signiﬁcantly greater reduction in HBV DNA and serum ALT
levelsin theentecavirtreatedpatients. The24 weekmortality
rates were similar in both treatment arms. Entecavir was well
tolerated and safety results were comparable in both treat-
ment groups. Continued followup is needed since the rate ofInternational Journal of Hepatology 7
entecavir-resistant HBV can substantially increase over time
in lamivudine-resistant HBV infection and potentially fatal
ﬂares may develop [81].
Entecavir was recently compared with tenofovir +
emtricitabine combination and tenofovir singly in an ongo-
ing multicentre study [82]. Improvements in CTP and
MELD scores as well as frequency of undetectable HBV DNA
at week 48 were similar in the three treatment arms.
Severe lactic acidosis with entecavir has been reported in
patients with decompensated liver [83].
12. Tenofovir
Tenofovir is an acyclic nucleotide analog with a molecular
structure similar to that of adefovir. It is approved for the
treatment of HIV infection and has in vitro activity against
both wild type and lamivudine-resistant HBV [84]. It is
administered as the prodrug tenofovir disoproxil fumarate
(TDF), and it is converted to tenofovir by plasmaesterases.
Tenofovir is phosphorylated to the active metabolite which
works as a chain terminator if incorporated into the
DNA chain and is a competitive inhibitor of natural
deoxyadenosine 50-triphosphate. Tenofovir is eliminated by
a combination of glomerular ﬁltration and active tubular
secretion. It is a signiﬁcantly more potent suppressor of
HBVreplicationthanadefovirandnodrug-resistantvariants
have been reported with 4 years of continuous treatment in
compensated HBV patients [85].
In the ongoing study reported in the previous section
[84], on 112 decompensated HBV patients given tenofovir,
tenofovir + emtricitabine, or entecavir, there were more
undetectable HBV DNA at week 48 in the tenofovir contain-
ing treatment arms (71%) than in the entecavir treatment
arm (33%) in patients with lamivudine resistant HBV.
HBeAg seroconversion was seen in 21 % and 13% of the
tenofovir and tenofovir/emtricitabine arms, respectively, but
not in the entecavir arm. Rates of nephrotoxicity, tolerability
and patient mortality were similar in the three treatment
armsthroughweek48.Continuedfollow-upofthesepatients
is needed to determine which of the newer antiviral agents
canoﬀerthebestrisk-beneﬁtratiointhischallengingpatient
population.
Although a tenofovir-based regimen may be preferred
in decompensated patients with lamivudine-resistant HBV,
there are concerns regarding the long-term safety of teno-
fovirin some HBV patients including nephrotoxicity and
metabolic bone disease [86, 87]. Patients with decompen-
sated cirrhosis are frequently malnourished and may have
low vitamin D levels. Prospective studies of bone density and
metabolic parameters during prolonged tenofovir treatment
are warranted as well as potential calcium and vitamin D
supplementation [88].
13. Summary
The availability of safe, orally administered antiviral agents
has revolutionized the management of chronic HBV and
opened up new treatment options for the large number of
patients with decompensated HBV cirrhosis worldwide who
previously had a dismal prognosis. These drugs can improve
or stabilize liver disease in patients who are not transplant
candidates or have no access to liver transplantation. For
these patients, the oral HBV antivirals may represent the
only hope for better quality or longer duration of survival
and reduced utilization of health care resources. The aim
of treatment in transplant candidates is to improve their
functional status such that they eventually might be removed
from the transplantation list. All patients with decompen-
sated cirrhosis, regardless of their serum HBV DNA level,
shouldbeconsideredfortreatment.Decompensatedpatients
withevidenceofactiveHBVreplication(i.e.,presenceofHBe
antigenemia and HBV DNA > 2000iu/mL,) are more likely
to derive beneﬁt from antiviral therapy.
Clinical studies have conﬁrmed that oral antivirals are
generally safe and eﬀective in suppressing HBV replication
in decompensated HBV cirrhosis with resultant stabilization
or improvement in liver disease. Clinical improvement is
slow and takes 3 to 6 months. It is not certain if starting
treatment earlier will improve the rate of response. Recent
eﬃcacy and safety data supports the use of entecavir as a
ﬁrst-line treatment option for nucleos(t)ide naive patients
with decompensated HBV cirrhosis [89]. Lamivudine and
telbivudine are also safe agents, but the risk of resistance
with prolonged therapy is ever present with potential for
worsening liver disease and increased risk of HBV recurrence
after transplantation and vigilance is important. Tenofovir
or entecavir monotherapy or adefovir add-on therapy are
possible rescue options should resistance occur. Studies
evaluating tenofovir monotherapy and combination therapy
in patients with decompensated cirrhosis are in progress.
However, continued follow-up from these ongoing studies
including long-term eﬃcacy, safety, and resistance data
are needed. Further studies are also needed to identify
the optimal agent(s) for patients with decompensated
lamivudine-resistant HBV cirrhosis. Decompensated HBV
patientsreceivingoralnucleos(t)ldeanaloguesmustundergo
frequentclinicalandlaboratoryassessmenttoinsuremedica-
tion compliance and surveillance for vIrological and clinical
response as well as drug side eﬀects, drug resistance, and
HCC.Asitisnotpossibletoidentifywhichpatientswithhigh
CTP or MELD scores will have poor short term prognosis, it
is advisable to refer all decompensated HBV patients for liver
transplant evaluation at presentation if available.
Antiviral therapy should be given to all potential liver
transplant candidates with decompensated HBV cirrhosis
and detectable HBV-DNA. Lamivudine resistance will result
in HBV recurrence in the posttransplant period [33].
Adefovir and entecavir can be given to rescue lamivudine
resistance, and initial use of these agents may minimize drug
resistance. Lamivudine plus low-dose intramuscular HBIg
(400–800U daily for 1 week, then monthly) is as eﬀective as
lamivudine plus high-dose intravenous HBIg in preventing
recurrent HBV infection resulting in a 5-year graft survival
of up to 85% at 10% of the cost [90]. Substituting HBIg
with adefovir 12 months posttransplant also prevent late
HBV recurrence and costs much less [91]. Lamivudine plus
adefovir combination from the time of listing has been
shown to be well tolerated, prevent lamivudine resistance8 International Journal of Hepatology
prior to transplant, rescued some patients from the need
for transplantation, and prevented recurrent HBV infection
following liver transplantation, regardless of baseline HBV-
DNA status [92]. Patients who were HBV-DNA negative
prior to transplant and those with sustained protective levels
of anti-HBs following posttransplant vaccination can be
safelygivenlamivudineorentecavirmonotherapy12months
aftertransplant.Antiviralprophylaxisshouldalsobegivenin
patientswhohavereceivedananti-HBc(+)livertopreventde
novo HBV infection.
Although the outlook for decompensated HBV patients
is bright with the advent of these oral antivirals, emphasis
should be placed on eﬀective treatment of patients with
chronic HBV infection to prevent them from progressing to
the decompensated state.
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